VYGR

Voyager Therapeutics Inc. Common Stock (VYGR)

Stock · NASDAQ · Health Care

$1.9as of 10/16/2026

Price chart

Open in TradingView

Active signals

200 SMA Touch0.0%
Resistance level
$3.75
Industry
Biotechnology: Biological Products (No Diagnostic Substances)

VYGR Signal Track Record

How signals performed across all stocks →

What VYGR's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.

SignalTimesMedian 20-session returnHigher after 20 sessions
Volume Spike34-4.3%41%
Bollinger Band Breakdown21+4.2%62%
Bollinger Band Breakout19-5.7%32%
200-Day Moving Average TouchActive now16-4.7%38%
Any 20-session window (baseline)-1.6%45%

Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.

About VYGR

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV)…

Sector
Health Care
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Employees
141

Fundamentals

1-day range
$2.14$2.26
Market cap
$189.12M
P/E (trailing)
—
P/E (forward)
-1.68
EPS (trailing)
$-1.81
Dividend yield
—
Beta
1.10
Avg. volume
572.2K
52-week range
$2.33$5.55
Next earnings: November 9, 2026 · EPS estimate $-0.44confirmed

How Voyager Therapeutics Inc. Common Stock Makes Money

Where the revenue actually goes — FY2025 annual results

market-wall.comTotalRevenue$40.37MR&D$134.67M (334%)SG&A$37.54M (93%)Tax$144.0K (0%)VYGR

Source: 10-K filed Mar 9, 2026 · via SEC EDGAR / Finnhub

Operating Income-$131.84M(-327%)

Forecasts

9 analyst ratings

Buy 94%
Hold 6%
Sell 0%
1-year price forecast
High
$25
+1215.8%
Median
$12
+531.6%
Low
$8
+321.1%

Voyager Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

  • VYGR
    Voyager Therapeutics Inc. Common Stock
    $1.9
    ▼ 7.77%
    Market cap $189.12MP/E —
    $2.33$5.55
  • DTIL
    Precision BioSciences Inc. Common Stock
    $5.77
    ▼ 6.48%
    Market cap $191.45MP/E —
    $3.53$9.62
  • IVVD
    Invivyd Inc. Common Stock
    $0.619
    ▼ 7.47%
    Market cap $194.15MP/E —
    $0.5277$3.07
  • CHRS
    Coherus Oncology Inc. Common Stock
    $0.99
    ▼ 7.48%
    Market cap $195.13MP/E —
    $1.01$2.62
  • OTLK
    Outlook Therapeutics Inc. Common Stock
    $0.488
    ▼ 2.40%
    Market cap $181.85MP/E —
    $0.1611$2.54
  • PLX
    Protalix BioTherapeutics Inc. (DE) Common Stock
    $2.62
    ▼ 2.96%
    Market cap $196.59MP/E 11.27
    $1.6$3.19
  • ALEC
    Alector Inc. Common Stock
    $1.84
    ▼ 3.66%
    Market cap $203.18MP/E —
    $1.09$3.4

P/E shows — for peers not currently carrying a live signal of their own.

Insider Activity

Insider Actions →
Acquired
270.0K
Disposed
0

Institutional Ownership

March 31, 2026

Total shares held
32.43M
Total value held
$123.36M
Institutional holders
130
Top holders this quarter
  • Unknown5.57M
  • Unknown3.50M
  • Unknown3.43M
  • Unknown3.00M
  • Unknown2.28M
  • Unknown1.15M
  • Unknown1.10M
  • Unknown1.05M
  • Unknown948.2K
  • Unknown875.6K

See the full, filterable feed with live charts on the MarketWall dashboard.

We use analytics to understand how market-wall is used. No personal data is sold.